EP262
Phase 2- Indications
- Chronic urticaria, Atopic dermatitis
Company intelligence / Profile preview
Escient Pharmaceuticals
San Diego, California, United Statesescientpharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Escient Pharmaceuticals developed first-in-class oral small molecule antagonists targeting novel neurosensory-inflammatory pathways via MRGPRs. Lead program EP262 showed promising preclinical results improving atopic dermatitis-like lesions and type II inflammation markers; early human studies indicated safety/tolerability at all tested doses. The pipeline also included EP547 for severe pruritus conditions such as cholestatic pruritus. The company was acquired by Incyte for $750M in May 2024 to expand Incyte’s portfolio of differentiated medicines addressing inflammatory diseases.
- Therapeutic areas
- GastroenterologyPulmonologyDermatologyImmunology
- Modalities
- Small molecules (oral antagonists)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
No major disclosed partnerships outside investors; now part of Incyte post-acquisition.
Beyond the preview
Go deeper on Escient Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Escient Pharmaceuticals.